GLP-1 / metabolic
Mazdutide
Approved abroadIBI362 / LY3305677 · GLP-1/glucagon dual agonist
First GCG/GLP-1 dual agonist approved (in China) for weight management.
What it is
A once-weekly oxyntomodulin-derived GLP-1/glucagon dual agonist, developed chiefly for the Chinese market.
How it works
Combines GLP-1 appetite/glucose control with glucagon-mediated energy expenditure and hepatic fat metabolism.
Studied for
Chronic weight management, T2D.
Regulatory status
Approved in China; not FDA-approved.
Safety
GI effects most common; glucagon component warrants heart-rate and metabolic monitoring.
What the community reports about Mazdutide
Aggregated from real community discussions across social platforms and forums. Anecdotal and self-reported — not causal, not medical advice.
The Innovent Biologics GLP-1/Glucagon dual agonist — sits between Sema/Tirz and Reta in mechanism (no GIP component); approved in China for obesity in 2024; positioned as A-Tier in one corpus tier list, suggesting emerging interest but limited US user experience.
Aggregated from public discussions and community forums, synthesized into themes and counts. Anecdotal and self-reported — not causal, not evidence a compound is safe or effective, not medical advice, and not a recommendation to use. No dosing shown.
Educational information only — not medical advice, and not a recommendation to use any compound. Many peptides here are not approved for human use; legal status and evidence quality vary and are noted above. This page contains no dosing information. Consult a qualified clinician before making any health decision.